Method of tumor regression with VEGF inhibitors
Methods of regressing or inhibiting a tumor in a subject by administering an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof such that the tumor is regressed or inhibited. The method of the invention results in a reduction of tumor size and inhibition of tumor metastases. This method is particularly useful for patients suffering from bulky, metastatic cancers.
1. A method of regressing or reducing the size of a tumor, comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof wherein the tumor is regressed or reduced, wherein the agent is a VEGF-specific fusion protein VEGFR1R2-FcΔC1(a).
2. The method of claim 1 , wherein the subject is a human subject having one or more tumors.
3. The method of claim 1 , wherein administration is subcutaneous, intraperitoneal, or intravenous.
4. A method of regressing or reducing metastases, comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof wherein metastases are regressed or reduce, and wherein the agent is VEGF-specific fusion protein VEGFR1R2-FcΔC1(a).
5. A method of treating a tumor such that the tumor is reduced in size, comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity, wherein the tumor is treated, and wherein the agent is VEGF-specific fusion protein VEGFR1R2-FcΔC1(a).
6. A method of inhibiting metastatic cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity, wherein the metastatic cancer is inhibited, and wherein the agent is VEGF-specific fusion protein VEGFR1R2-FcΔC1(a).